clinical trial · NCT06504615
Observational Study of Patients Treated With Nivolumab and Chemotherapy for Advanced or Metastatic Esophageal, Gastroesophageal or Gastric Cancer in France
Bristol-Myers Squibb·—·active not recruiting·n = 208
Gastric AdenocarcinomaGastro-esophageal Junction AdenocarcinomaEsophageal Adenocarcinoma (EAC)Esophageal Squamous Cell Carcinoma (ESCC)nivolumab + chemotherapy
brief summary
A study to estimate the overall survival in real-life conditions in France of adult participants treated with nivolumab in combination with chemotherapy as first-line treatment for gastric and gastroesophageal junction cancer.
started
Dec 10, 2024
primary completion
Aug 31, 2028
completion
Aug 31, 2028
last updated
Apr 3, 2026
official title
A French, Prospective, Observational, Multicenter Study of Patients Treated With Nivolumab Plus Chemotherapy as First Line Treatment in Advanced or Metastatic Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma or Gastric Adenocarcinoma [METAGIO]
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol